We have studied these possibilities in the hope of advancing the treatments of Parkinson's disease and of psychosis. To this end we used adenylate cyclase from mouse caudate to screen agents that can affect the symptoms of Parkinson's disease. These included drugs that stimulate the dopaminergic system in man or animals and inactive metabolites and precursors thereof and compounds that activate or inhibit the cholinergic system, which counterbalances the dopaminergic one in the brain (7, 8) .
Most major antipsychosis drugs can induce a parkinsonian syndrome (1) whereas, conversely, some antiparkinsonism agents have caused psychotic episodes (2, 3) . The (4) (5) (6) . Because this cyclase is cardinally involved in the receipt and amplification of messages by postsynaptic neurons at dopaminergic synapses, it was possible that dopaminergic antiparkinsonism agents may function by activating this cyclase. This consideration raised questions also about effects of some nondopaminergic drugs, acting on cholinergic neurons, that can relieve or aggravate the symptoms of parkinsonism while they can aggravate or relieve, respectively, psychotic states.
We have studied these possibilities in the hope of advancing the treatments of Parkinson's disease and of psychosis. To this end we used adenylate cyclase from mouse caudate to screen agents that can affect the symptoms of Parkinson's disease. These included drugs that stimulate the dopaminergic system in man or animals and inactive metabolites and precursors thereof and compounds that activate or inhibit the cholinergic system, which counterbalances the dopaminergic one in the brain (7, 8) .
MATERIALS AND METHODS Animals. These were 5-to 6-week-old male Swiss albino mice, weighing 23-27 g, maintained on Purina Chow and water ad lib., and kept in an air-conditioned room on a 12-hr lightto-darkness cycle. The experiments were started in midday by decapitating the animals in a cold room. The brains were removed within 30 sec and placed on a cold watch glass. The lateral ventricles were entered by removing their roofs. The exposed heads of the caudates were scooped out with forceps.
Determination of Dopamine-Stimulated Adenylate Cyclase Activity. The methods are essentially those developed in Greengard's laboratory (9) . All fragments of both caudates (about 30 mg) were placed in Krebs-Ringer bicarbonate solution, pH 7.4, which had been gassed for 2 min with 5% CO2/ 95% 02. They were homogenized in 0.5 ml of 50 mM Trismaleate buffer, pH 7.4, containing 12.5 mM theophylline, 0.25 mM ethylene glycol-bis(Q-aminoethyl ether)-NN'-tetraacetic acid, and 2.5 mM MgSO4. Aliquots (0.4 ml) of the homogenates were placed in 5-ml Pyrex tubes that had previously been equilibrated to 30°in an orbital water bath. The control tubes received 50 gl of H20. The experimental tubes received different additives in different series of experiments, the concentrations of which are given below. In one series, 50 ,ul containing either dopamine or a dopaminergic substance was added. In another series, the tubesi received 25 ,ul containing one of the above substances plus 25 jul containing-an inhibitor, a metabolite, or a precursor thereof. In another series, the precursors and metabolites were tested in various concentrations for activation of the cyclase. In still another series, the metabolites were screened for inhibition of the dopamine-dependent activation. Finally, some cholinergic and anticholinergic agents were screened for activation or inhibition of the cyclase.
The reaction was started by adding 50 jul of a 0.5 mM solution of ATP with mixing and then incubating in a 30°orbital water bath. After 2.5 min, the reaction was terminated by immersion of the tubes into a boiling water bath for 2 min. The homogenates were centrifuged at 1500 X g for 5 min. The supernatant solutions were quick-frozen until analyzed for adenosine 3': 5'-cyclic monophosphate (cyclic AMP) according to Gilman (10) .
The results of the cyclic AMP determinations were used as follows. We first computed the mean ±SEM of both nonstimulated and stimulated samples. From these we calculated the net dopamine-stimulated cyclic AMP produced by subtracting the mean nonstimulated activities from each of the stimulated ones and computing mean ±SEM of the differences. Table 1 shows the results of screening some dopaminergic drugs that had shown antiparkinsonism activity in man (11) and some dopaminergic agents that have proved to be active in animals but have not yet been studied in man (12) . Table 2 shows the results with some precursors of dopaminergic drugs (see ref. 13 ) and with some metabolites thereof (see refs. 13 and 14) . Table   3 The degree of activation found with 10 MM concentrations of activator ( Fig. 1) decreased when the concentrations of the activators were increased, except for dopamine which again (9) did not show this autoinhibition. When we investigated the possibility that two activators can display additive stimulation, we found that the activation produced by 10MuM concentrations of the activators was potentiated by adding equimolar concentrations of dopamine (Fig. 2) . Concomitantly, dopamine at 10 MM lessened the inhibition caused by excess.activator. As we discuss below, these trends might explain the paradoxical synergism and antagonism between some aporphines and Ldopa encountered by us while investigating the treatment of Parkinson's disease in man (15, 16) .
RESULTS
Precursors and Metabolites of Dopaminergic Drugs. In selective inhibition could be reversed in all instances by increasing the concentration of dopamine, suggesting competitive inhibition.
Atropine and acetylcholine were investigated in detail because the first is the prototype of anticholinergic drugs used for treating parkinsonism and the second is the natural activator of the cholinergic system which aggravates the symptoms of parkinsonism. Lineweaver-Burk type experiments (18) showed these drugs to be selective competitive inhibitors of the dopamine-stimulated activity of this cyclase (Fig. 3) . The inhibitor constant, K1, was 1.26 X 1O-7 M for acetylcholine and 5.4 X 1O-7 M for atropine; the Michaeles constant, Km for dopamnine was 2.17 X 10-9 M. The cyclase itself was not activated nor was its dopamine-induced activation increased by concentrations of atropine or acetylcholine between 0.5 and 10 juM. DISCUSSION Greengard and associates (9, 19, 20) have provided evidence that the adenylate cyclase studied here is a cardinal constituent of the dopaminergic receptors. The enzyme initiates postsynaptic neurotransmission and the amplification of it-in dopaminergic neurons. Their further discovery (4-6) of a highly selective inhibition of the dopamine-sensitive activity of this cyclase by antipsychosis drugs strengthened the dopamine theory of psychosis. This effect of antipsychosis drugs raised questions about the role of the enzyme in Parkinson's disease and in its treatment, in view of the pharmacological reciprocity between psychosis and extrapyramidal function. Indeed, the dopaminergic antiparkinsonism drugs had an opposite effect to that of the antipsychosis drugs-namely, stimulation of the cyclase. Such a stimulation was indeed restricted to the active forms of dopaminergic drugs because metabolites and precursors were as inactive in stimulating the cyclase in vitro as they have been in stimulating mammalian or human brain experimentally in vivo (2) . The one exception-the inhibition of the action of apomorphine on the enzyme by O-methylated apomorphines-duplicated experiments in animals (17) and perhaps simulated the loss of potency of aporphines with time encountered in the treatment of parkinsonism (16) .
The inhibition of the cyclase by high concentrations of ac- tivator and the reversal of this inhibition by dopamine are compatible with the concomitant antagonism and synergism encountered between some aporphines and L-dopa in patients with Parkinson's disease (15, 16) . This phenomenon consisted of an increase in the antiparkinsonism effects of L-dopa by apomorphine (15) or N-propylnoraporphine (16) and the blocking of the dyskinesia produced by L-dopa.
Whereas the activation of this enzyme by dopamine receptor activators readily conformed with several precedents, the actions of the cholinergic and anticholinergic compounds must be reconciled with two discrepancies: (i) these two classes of compounds acted similarly with regard to this enzyme although they opposed each other's pharmacological effects in animals and man, and (ii)they acted as inhibitors of the cyclase, which conflicts with the antiparkinsonism effects of the anticholinergic drugs.
On the first of these counts, this cyclase behaved like one of the classical cholinergic receptors which bind both cholinergic and anticholinergic chemicals, albeit with different constants (21) . The dopaminergic enzyme studied here showed a weaker binding constant for acetylcholine than for atropine, thus behaving like a cholinergic site. We cannot yet suggest a plausible role for this cholinergic function of dopaminergic receptors.
The second count is only weakly related to some precedents. Cholinergic drugs, for example, do alleviate psychoses while aggravating parkinsonism and have acted on the cyclase concordantly (7, 8) . When given with L-dopa, anticholinergics are somewhat more potent as antiparkinsonism agents (22, 23) . This suggests that, in addition to anticholinergic action, these drugs have a hitherto unsuspected inhibitory effect on the cyclase which tends to be reversed by the dopamine synthesized from L-dopa. These parallelisms break down, however, when one considers that anticholinergics, which are hallucinogens, have acted in the opposite direction in tests such as these (4) (5) (6) 24) .
The sum of this evidence proves that the regulatory functions of this cyclase have not been fully defined as yet. It is obviously desirable that this enzyme be tested for its responses to hallucinogenic drugs. We are currently determining whether its activity is quantitatively correlated with neurological responses to drugs as opposed to the qualitative parallelisms drawn thus far. These uncertainties, viewed with the fact that the caudate is a large complex cerebral structure, make it probable that we have missed some important regulatory function of the cyclase in the caudate, a function perhaps radically different from any of those mentioned here. Proc. Nati. Acad. Sci. USA 74 (1977) 
